Mark Fawcett - Apollo Medical Independent Director
| 3AM Stock | EUR 39.80 1.20 3.11% |
Director
Mr. Mark Fawcett is an Independent Director of Apollo Medical Holdings, Inc. Mr. Fawcett was a member of the Board since January 2016. Since 2002, Mr. Fawcett has served as Senior Vice President and Treasurer of Fresenius Medical Care Holdings, Inc. and its subsidiaries. FMCH is a whollyowned subsidiary of Fresenius Medical Care AG Co. KGaA . FMS is a leading provider of chronic kidney failure products and services. Prior to joining FMS, Mr. Fawcett was a director of corporate finance at BankBoston beginning in 1997. Mr. Fawcett held various positions of increasing responsibility beginning in 1988 with Merrill Lynch in New York and London, and then at The Bank of New York since 2016.
| Age | 52 |
| Tenure | 8 years |
| Professional Marks | MBA |
Apollo Medical Holdings Leadership Team
Elected by the shareholders, the Apollo Medical's board of directors comprises two types of representatives: Apollo Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apollo. The board's role is to monitor Apollo Medical's management team and ensure that shareholders' interests are well served. Apollo Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apollo Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Li Yu, Independent Director | ||
| John Chiang, Independent Director | ||
| Ernest Bates, Independent Director | ||
| Kenneth Sim, Chairman of the Board, Co-Chief Executive Officer, Executive Director | ||
| Mitchell Kitayama, Lead Independent Director | ||
| Linda Marsh, Director | ||
| Thomas Lam, President, Co-Chief Executive Officer, Director | ||
| Albert Young, Chief Administrative Officer | ||
| Mark Fawcett, Independent Director | ||
| Brandon Sim, Chief Operating Officer, Chief Technology Officer, Vice President of Engineering | ||
| David Schmidt, Independent Director | ||
| Michael Eng, Independent Director | ||
| Eric Chin, Chief Financial Officer, Interim Co-Chief Operating Officer, Secretary | ||
| Adrian Vazquez, Co-Chief Medical Officer | ||
| Matthew Mazdyasni, Director |
Apollo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apollo Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.28 B | |||
| Price To Book | 2.60 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 1.14 B | |||
| EBITDA | 112.08 M | |||
| Net Income | 49.05 M | |||
| Total Debt | 203.39 M | |||
| Cash Flow From Operations | 70.33 M | |||
| Number Of Employees | 15 | |||
| Market Capitalization | 197.6 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Apollo Stock
Apollo Medical financial ratios help investors to determine whether Apollo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Apollo with respect to the benefits of owning Apollo Medical security.